Harris A L, Dowsett M, Jeffcoate S L, Smith I E
Eur J Cancer Clin Oncol. 1983 Apr;19(4):493-8. doi: 10.1016/0277-5379(83)90112-8.
The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid. Aminoglutethimide (AG) 250 mg twice a day was as effective as AG 250 mg 3 times a day or AG 250 mg 4 times a day. Side-effects were less at the lowest dosage and were age-related. On-treatment oestrone levels were higher in non-responders to treatment. Lower doses of AG than are currently used may be as effective therapeutically.
在36例晚期绝经后乳腺癌女性患者中，研究了氨鲁米特剂量对雌酮、雌二醇和硫酸脱氢表雄酮（DHAS）水平的抑制作用，所有患者均每日两次接受20mg氢化可的松作为糖皮质激素替代治疗。氨鲁米特（AG）每日两次250mg与每日三次250mg或每日四次250mg的效果相同。最低剂量时副作用较少，且与年龄相关。治疗无反应者治疗期间的雌酮水平较高。低于目前使用剂量的AG可能在治疗上同样有效。
